Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 4: The role of JAK inhibition.

Research paper by Leonard H LH Calabrese, Tiphaine T Lenfant, Cassandra C Calabrese

Indexed on: 28 Aug '20Published on: 28 Aug '20Published in: Cleveland Clinic journal of medicine


This review focuses an alternative strategy utilizing small molecules to inhibit a key signal-transduction pathway, the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. The JAK-STAT pathway mediates biologic activity for a large number of inflammatory cytokines and mediators. Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.